Infos über Microcide Pharma... - 500 Beiträge pro Seite

[Icon]

Kann mir jemand etwas über Microcide Pharmaceut.
sagen ???? ( WKN 900791 )

Danke Icon

[Traumtaenzer]

Business Description:
Microcide Pharmaceuticals Inc., discovers, develops and commercializes new and different
antibiotics for the treatment of serious bacterial, fungal and viral infections. The company meets the
problem of bacterial drug resistance through two themes, They are Targeted Antibiotics, which
develops novel antibiotics and antibiotic potentiators to address the problems of existing bacterial
resistance and Targeted Genomics which uses bacterial genetics to discover new antibiotics and
other novel treatments for bacterial disease. During the year, company formed Iconix
Pharmaceuticals, Inc. The company became publicly held in 1996.



General Stock Information


Common Shares:
11,137,922
Current Mkt Cap:
96,766,266
Sales/Revs 1998:
11,181,000

Share Type: Common
Exchanges:
NAS
Major Industry: Miscellaneous
Sub-Industry: Medical Services
Products: Industrial Services
P/E Ratio: N/A



Executive Office:
850 MAUDE AVENUE
MOUNTAIN VIEW CA 94043
Telephone:
[phone]
Employees:
133

[Traumtaenzer]

MICROCIDE PHARMACEUTICALS ANNOUNCES PHASE I CLINICAL
TRIALS UNDERWAY WITH RWJ-54428, A NOVEL CEPHALOSPORIN
ANTIBIOTIC RECEIPT OF MILESTONE Payment From R. W.
Johnson Pharmaceutical Research Institute

PR Newswire - Monday, November 22, 1999

MOUNTAIN VIEW, Calif., Nov 22, 1999 /PRNewswire via COMTEX/ -- Microcide Pharmaceuticals, Inc. (Nasdaq: MCDE) today announced
commencement of Phase I clinical trials of the antibiotic RWJ-54428, a novel member of the cephalosporin class first synthesized at Microcide as
MC-02,479. With entry into Phase I, Microcide will receive a significant milestone payment from the R. W. Johnson Pharmaceutical Research
Institute (RWJPRI), a subsidiary of Johnson & Johnson (NYSE: JNJ).

"We`re pleased to have advanced this compound, which is so well equipped to treat resistant infections, into the clinic with our colleagues at
RWJPRI," said Jim Rurka, President & CEO of Microcide. "For Microcide, this is our first antibiotic discovery to reach clinical trials, so it`s an
important milestone event for the Company, and we`re proud to have achieved it."

RWJ-54428 is the result of a collaborative research effort between Microcide and RWJPRI, which commenced in November 1995. The research goal
of the program has been the development of a novel beta-lactam antibiotic with potent, bactericidal activity against susceptible and resistant strains
of Gram-positive bacteria such as staphylococcus, enterococcus and streptococcus. The incidence of antibiotic-resistant bacterial infections
continues to increase worldwide, and clinicians urgently need additional therapeutic agents to help combat them.

Microcide is a biopharmaceutical company whose mission is to discover, develop and commercialize novel antimicrobials for the improved treatment
of serious bacterial, fungal and viral infections. The Company`s discovery and development programs address the growing problem of bacterial drug
resistance and the need for improved antifungal and antiviral agents through two principal themes: (i) Targeted Antibiotics, which focuses on
developing novel antibiotics and antibiotic potentiators to directly address existing bacterial and fungal resistance problems, and (ii) Targeted
Genomics, which utilizes bacterial, fungal and viral genetics to discover new classes of antimicrobials and other novel treatments for infectious
diseases.

The statements in this press release that relate to Microcide developing new antibiotics for human health applications are forward-looking statements.
Such forward-looking statements involve risks and uncertainties including, without limitation, the following. There is no assurance that any
compounds discovered will successfully proceed through pre-clinical development and clinical trials, obtain requisite regulatory approvals for
marketing or result in a commercially useful product. For a discussion of other risks and uncertainties affecting Microcide`s business, see the
Company`s annual report on Form 10-K for the year ended December 31, 1998. Actual results and timing of certain events could differ materially from
those indicated in the forward-looking statements as a result of these or other factors.

SOURCE Microcide Pharmaceuticals, Inc.

... so das war erst mal alles was ich gefunden habe.
Hoffe ich konnte dir ein bißchen helfen (ach ja am NASDAQ unter MCDE gehandelt)

Gruß
Traumtaenzer

[Icon]

Vielen Dank Traumtaenzer für die schnellen und ausführlichen Infos.

Gruß Icon

[JSK]

MCDE steht/stand auf meiner Einkaufsliste. ist in den letzten Tagen aber schon prächtig gekommen. Werde noch auf einen Rückschlag warten, wenn es einen gibt.
:O

[maechuber]

Toll !

Jetzt weiß auch ein wenig mehr. Der Wert war mir unter www.muster-depot.de ins Auge gesprungen. Andre Fischer - derzeitige Gewinner des Börsenspiels- hat sich die Aktie zu 11 Euro ins Depot gelegt. Noch am Freitag legte die Aktie in USA gut zu.
Vielleicht kann ja noch jemand mehr über den Wert sagen.
Danke für die bisherigen Infos

Maec-huber

[tradi]

Hallo,

Ich würde ebenfalls etwas mehr über diese Aktie erfahren!!
Vielleicht kann ja jemand was dazu sagen!!

Vielen Dank


bis dann....

tradi

[maechuber]

Eines noch....

vielleicht kann mir jemand von euch noch den Link nennen, wie ich aktuelle Kurse aus USA bekomme - denke, daß microcide auch am Montag nochmal zulegen und würde dies gern direkt verfolgen.

Maec-huber

[Traumtaenzer]

...probier mal www.financialweb.com, NASDAQ-Kürzel MCDE
Gruß
Traumtaenzer

[maechuber]

Vielen Dank !

Ging ja echt fix

Gruß maec-

[PaGaa]

Microcide phar. hat Heute über 33% gemacht.
Hat sie eigenen Grund dafür?? Ist das nur "Morphosys-Effekt" ??
Wird die Aktie diese Woche halten oder geht sie Morgen schon in den Keller?
Stelle zu viel Fragen - ich weiß
(bin ziemlich neu im Geschäft)